Today’s cyclodextrin is a cool, general review on medicinal, food and cosmetics applications of natural compounds, supported by CDs, of course. Great work from Aristotle University of Thessaloniki (AUTH) & APIVITA SA – Konstantinos Gardikis et al.
Production and uses of glyco-engineered CAR-T cells for the improvement of immunotherapy compositions for treatment of solid tumors. This therapeutic tools seems promising to cure cancer, reduce (recurrent) tumor growth and tumor burden, as well as to prevent relapse.
VIB & Ghent University – Nico Callewaert; Nele Festjens; Elien De Bousser
today’s cyclodextrin:
The use of CDs in soil remediation has a long history. Here is the most recent chapter.
The removal efficiency of antimony (Sb) and naphthalene (Nap) from a combined contaminated soil was studied by carboxymethyl-β-cyclodextrin (CMCD) leaching and reveal its remediation mechanisms. The results show that the highest removal efficiencies of Sb and Nap were 94.82% and 93.59%, respectively. The breakthrough curves show that CMCD had a stronger inclusion capacity of Nap than Sb, and Sb could enhance the adsorption capacity of Nap, while Nap weakened the adsorption of Sb during CMCD leaching. CMCD is a good eluant for remediating soil contaminated by a combination of heavy metals and polycyclic aromatic hydrocarbons (PAHs), and its remediation mechanisms depend on the complexation reactions between the surface functional groups and inclusion reactions in the internal cavities.
today’s cyclodextrin:
CD-based detoxifying agent kit both for detoxifying CO and HCN in a living body simultaneously, with two NCEs of different cyclodextrin dimers and water-soluble metal porphyrins having a bivalent central metal.
Doshisha University – Hiroaki Kitagishi
A very recent patent application from ASDERA on using hyproxypropyl-alfa-cyclodextrin formulated with a medium chain fatty acid (ideally a cproic acid derivative) for the ORAL delivery is the CD. Similarly to our interests, the CD itself is proposed to be the therapeutic agent and the oral delivery would open a new solution to treat cancer or a neurodegenerative, cardiovascular, metabolic, inflammatory, autoimmune, age-related, or viral disease or disorder in a subject which is currently only possible via parenteral administration. Keep an eye on Knut M. Wittkowski as his research is highly important. Overcoming the current issues with CD dosing is an unsolved problem in this research area.
See the full patent here: Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
Just because we think functionalizing cyclodextrin with biotin is fancy and could have a great variety of uses.
This paper describes a new route to the surface modification of bismuth oxide nanoparticles (Bi2O3 NPs) using functionalized beta-Cyclodextrin (β-CD) as a biocompatible system. The synthesis of Bi2O3 NP was done using PVA (polyvinyl alcohol) as the reductant and the Steglich esterification procedure for the functionalization of β-CD with biotin. Ultimately, the Bi2O3 NPs are modified using this functionalized β-CD system. The antibacterial and anticancer effects of the surface-modified Bi2O3 NP system were also investigated.
Jogy Alex and Thomas Mathew
See the full article here: Surface Modification of Bi2O3 Nanoparticles with Biotinylated β-Cyclodextrin as a Biocompatible Therapeutic Agent for Anticancer and Antimicrobial Applications
In nature, almost all cells are covered with a complex array of glycan chains namely sialic acids or nuraminic acids, negatively charged nine-carbon sugars, which is considered for their great therapeutic importance since long back. Owing to its presence at the terminal end of the lipid bilayer (commonly known as terminal sugars), the well-defined sialosides or sialoconjugates have served a pivotal role on the cell surfaces, and thus, the sialic acid-containing glycans can modulate and mediate a number of imperative cellular interactions. Understanding the sialo-protein interaction and their roles in vertebrates in regard of normal physiology, pathological variance, and evolution has indeed a noteworthy journey in medicine.
This is a concise overview of the structure, linkages in chemical diversity, and biological significance followed by chemical and enzymatic modification/synthesis of sialic acid containing glycans. More focus is attempted on the recent advances, opportunity, and moreover, growing impact of sialosides and sialoconjugates in future drug discovery and development.
Priyanka Bose, Dr. Manoj Kumar Jaiswal, Vinod Tiwari et al – Banaras Hindu University
See the full article here: Growing impact of sialic acid-containing glycans in future drug discovery
Wrestling with Lipinski’s rule of 5
The chemist introduced the guidelines more than 25 years ago. Drug designers still disagree about their value.
Even Lipinski counts himself among those that don’t think the rule of 5 should be hard and fast. “I am still slightly taken aback by how some people want strict guidelines without consideration of nuance,” says the chemist, who retired from Pfizer in 2002 and is now a consultant. “At heart, I am an experimentalist, and I believe that generally, experimentation trumps calculation. So one should try hard to measure the properties of an interesting compound even if the calculations on that compound may not look too promising.”
See more about Lipinski’s rule of 5 here
Biden’s plan allocates $25 billion, an increase of about $6.5 billion from 2023, for activities authorized by the Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act. That legislation aims to boost the global competitiveness of US research by allowing major increases in funding for the National Science Foundation (NSF), the Department of Energy’s (DOE) Office of Science, and the National Institute of Standards and Technology (NIST).
See the full article here: Science ranks high in Biden’s 2024 budget plan
today’s cyclodextrin:
is certainly a fancy application that has been around for years, yet its commercial application is still waiting around the corner: self-healing systems. This field is pioneered by the group of Akira Harada at Toyota Motor Corporation (earlier Osaka University), by now, there are several other groups working on creating such networks. In the first article, you can find some videos and animations to understand how the concept works.
The main uses proposed so far have been in the automotive industry as car paint or surface cover, similar to cellphones.